Your browser doesn't support javascript.
loading
Sertoli - Leydig cell tumor with retiform areas and overgrowth of rhabdomyosarcomatous elements: case report and literature review.
Burnik Papler, T; Frkovic Grazio, S; Kobal, B.
Affiliation
  • Burnik Papler T; Division of Obstetrics and Gynecology, University Medical Centre Ljubljana, Slajmerjeva 3, 1000, Ljubljana, Slovenia.
  • Frkovic Grazio S; Department of Obstetrics and Gynecology, University Medical Centre Ljubljana, Slajmerjeva 3, 1000, Ljubljana, Slovenia.
  • Kobal B; Department of Gynecological Pathology, Division of Obstetrics and Gynecology, University Medical Center Ljubljana, Ljubljana, Slovenia.
J Ovarian Res ; 9(1): 46, 2016 Jul 30.
Article in En | MEDLINE | ID: mdl-27473538
ABSTRACT

BACKGROUND:

Sertoli - Leydig cell tumors (SLCTs) are sex-cord stromal tumors that account less than 0.5 % of primary ovarian neoplasms. They are mostly benign and occur in reproductive age women. Variants with heterologous mesenchymal elements are exceptionaly rare. The usual presentation of SLCTs is with signs of androgen excess as majority of them produce androgens. CASE PRESENTATION We present a case of a SLCT occurring in a 70 year old woman. Her presenting complaint was abdominal distension and pain. She had no signs of androgen or estrogen excess. Transvaginal ultrasound (TVUS) and CT scan showed a multilocular adnexal tumor and level of CA 125 was raised. A complete cytoreduction was achieved with surgical procedure. Histopathological examination revealed moderately differentiated SLCT with retiform areas and owergrowth of heterologous component in form of embrional rhabdomyosarcoma (RMS). She returned 7 months after the surgery with a large abdominal mass, ascites, right- sided hydronephrosis and massive pulmonary embolism. Due to the widespread disease and her poor general condition, she received only palliative care. She died 15 days after the admission. No autopsy was performed.

CONCLUSIONS:

Due to the rarity of SLCTs, especially those with retiform areas and heterologous elements, their management remains challenging. There is no firm evidence that adjuvant chemotherapy is effective in improving survival in SLCTs with malignant heterologous elements. Further studies with a higher number of cases and a longer follow-up are needed to better predicting the prognosis and determine the role of chemotherapy in such cases.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Sertoli-Leydig Cell Tumor / Rhabdomyosarcoma, Embryonal Type of study: Prognostic_studies Limits: Aged / Female / Humans Language: En Journal: J Ovarian Res Year: 2016 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Sertoli-Leydig Cell Tumor / Rhabdomyosarcoma, Embryonal Type of study: Prognostic_studies Limits: Aged / Female / Humans Language: En Journal: J Ovarian Res Year: 2016 Document type: Article Affiliation country: